Drug intelligence / Profile preview

cAMP regulator

Development stage: Preclinical
Lead developer: GNI Group
Modality: Small Molecules

Overview

cAMP regulator is a preclinical small molecule drug candidate being developed by GNI-EPS Pharmaceuticals, a subsidiary of GNI Group, for the treatment of fibrotic diseases. The compound is designed to modulate the levels of cyclic adenosine monophosphate (cAMP), a critical intracellular second messenger. In the context of fibrosis, elevated cAMP levels are generally associated with the inhibition of fibroblast-to-myofibroblast differentiation, reduced collagen synthesis, and enhanced degradation of the extracellular matrix. By regulating cAMP signaling pathways, this therapeutic approach aims to halt or reverse the progression of pathological scarring in various organs.

Other names: GNI-EPS Pharmaceuticals-cAMP Regulator-small molecule-Fibrotic diseases

Beyond the preview

Go deeper on cAMP regulator.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on cAMP regulator.

Explore the full profile